Building on the success of this year's event, the 3rd Annual European Life Science CEO Forum, an exclusive and highly transactional forum for investing and partnering in the Biotech and Pharma industry is back at the SIX Swiss Exchange, Zurich. Attended by 300 delegates over a two-day program, the forum will provide you with truly excellent networking opportunities, allowing access to some of the leading players in the industry. More over, the 500 meeting slots available through the online 121 meeting system makes this event a must for companies wishing to meet with their peers, engage with leading investors and forge new partnerships.

Program features:

• Plenary panel sessions covering investment, partnering and M&A, investing in vaccines, investing in medical devices and an interactive panel session.
• 60 company presentations by public and private, venture funded companies
• 10 Pharma partnering workshops covering partnering opportunities in the major therapeutic areas of CNS, immunology, oncology and vaccines, with presentations from Bristol-Myers Squibb, Merck & Co., Merck Serono, Novartis, Nycomed and Roche.
• 500 meeting slots with online 1–to–1 meeting system
• Networking Reception on the evening of the 11^th Feb
• The 2010 DyoDelta European Life Science Innovation Awards

Speakers & Chairs to date include:

• Genghis Lloyd-Harris, Partner, Abingworth Management Ltd
• Simon Buckingham, President, Global Corporate and Business Development, Actelion Pharmaceuticals
• Ekaterina Smirnyagina, Partner, Alta Partners
• Markus Hosang, General Partner, BioMedPartners
• Lubor Gaal, Executive Director, Head of Europe, Strategic Transaction Group, Bristol-Myers Squibb
• Stephanie Léouzon, Senior Advisor, Credit Suisse
• Wolfgang Renner, CEO, Cytos Biotechnology AG
• Dimitri Dimitriou, CEO, DyoDelta Biosciences
• Beth Jacobs, Managing Partner, Excellentia Global Partners
• Nigel Sheail, Head Corporate Business Development, F. Hoffmann-La Roche Ltd.
• Shelagh Wilson, Vice President, Head of European CEEDD, GSK
• Thomas Klaue, CFO, Medigene
• Margaret Beer, Senior Director, Scientific Liaison, Licensing and External Research, Europe, Merck & Co.
• Roel Bulthuis, Head of Merck Serono Ventures, Merck Serono Ventures
• Anthony Hartley, Executive Director, Morgan Stanley
• David Chiswell, CEO, Nabriva Therapeutics AG 
• Denise Pollard-Knight, Managing Director, Nomura Phase4 Ventures
• Esteban Pombo Villar, Head of Strategic Alliance Management EU, Novartis Pharma
• Markus Goebel, Managing Director, Novartis Venture Funds
• Carlos de Sousa, Vice-President Licensing, Business Development, Nycomed
• Alex Chanas, Senior Director, Worldwide Licensing and Business Development, Pfizer, Inc.  
• Fintan Walton, CEO, PharmaVentures Ltd
• Alexandra Goll, Partner, TVM Capital
• Ken Cunningham, CEO, SkyePharma Plc                     
• Antoine Papiernik, Managing Partner, Sofinnova Partners
• Simon Turton, Managing Director Healthcare, Warburg Pincus LLC
• Peter Llewellyn-Davies, CFO, Wilex AG

You can find a list of past presenters here and details on our previous event programs here.

Sign up as a presenting company now to avoid disappointment!  Presenting places are limited and the package includes:

• A 15 minute presentation slot
• 2 complimentary guest passes including staff
• Access to our online 121 meeting system with publication of your profile
• Access to all workshops, presentations and panel discussions
• A full-page company profile in the conference guide
• Company listing on the event website
• Distribution of company marketing material at the conference
• Networking lunches, coffee breaks and dinner during the conference 

For further details and information on presenting fees, please contact Emma on + 44 (0) 20 7405 5563 or email emma@sachsforum.com

For delegate attendance only, registrations are now open and the fee is € 1495. For further details and to register, please use our online registration form.

The European Life Science CEO Forum promises to be an excellent opportunity to showcase your company to some of the leading global investors and corporates.

Please visit our website for regular updates. We look forward to hearing from you soon.